Celldex Therapeutics, Inc. (CLDX): Price and Financial Metrics
Today's Latest Price: $15.38 USD
Oct 29 4:00pm Add CLDX to Watchlist Sign Up
Buy & Hold Grade
Peer Grade Industry Rank
CLDX Stock Summary The ratio of debt to operating expenses for Celldex Therapeutics Inc is higher than it is for about just 7.79% of US stocks. CLDX's price/sales ratio is 136.77; that's higher than the P/S ratio of 97.8% of US stocks. In terms of volatility of its share price, CLDX is more volatile than 97.54% of stocks we're observing. Stocks that are quantitatively similar to CLDX, based on their financial statements, market capitalization, and price volatility, are MESO, KLIC, CBIO, ETTX, and LOGC. Visit CLDX's SEC page to see the company's official filings. To visit the company's web site, go to www.celldex.com.
CLDX Price/Volume Stats
Celldex Therapeutics, Inc. (CLDX) Company Bio
Celldex Therapeutics is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. The company was founded in 2004 and is based in Hampton, New Jersey.
CLDX Latest News Stream
All News Types
Acquisition Commentary Downgrade Earnings Mgmt Change New Coverage (Bearish) New Coverage (Bullish) Product News PT Lowered PT Set (Bullish) Rating Reiterated (Bullish) Rating Reiterated (Neutral) Stock Offering
Loading, please wait...
Latest CLDX News From Around the Web
Below are the latest news stories about Celldex Therapeutics Inc that investors may wish to consider to help them evaluate CLDX as an investment opportunity.
Celldex Therapeutics (CLDX) is a development-stage pharmaceutical company. It was once a high-flyer, before its lead candidate failed a Phase 3 trial in 2015. More recently, before the CDX-0159 news was announced in June, it was selling at about $3.00 per share. On September 30, 2020, Celldex closed at $14.83...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc (NASDAQ: XLRN ) (announced Health Canada approval of luspatercept for RBC transfusion-dependent anemia associated with beta-thalassemia) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Adial Pharmaceuticals Inc (NASDAQ: ADIL )(announced EUA for antibody test for COVID-19) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cardiff Oncology Inc (NASDAQ: CRDF ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Fate Therapeutics Inc (NASDAQ: FA...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 28) 10X Genomics Inc (NASDAQ: TXG ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Beigene Ltd (NASDAQ: BGNE ) Cardiff Oncology Inc (NASDAQ: CRDF ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Evogene Ltd (NASDAQ: EVGN ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) InVitae Corp (NYSE: NVTA ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Kura Oncology Inc (NASDAQ: KURA ) Lantern Pharma Inc. (NASDAQ: LTRN ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Prelude Therapeutics Incorporated (NASDAQ: PRLD ) (listed Thursday) Seattle Genetics, Inc. (NASDAQ: SGEN ) Shockwave Medical Inc...
HAMPTON, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in Fireside…
Tricida suffers setback on Veverimer front Tricida Inc. (TCDA) reported that the FDA has given a Complete Response Letter to the company for its application pertaining to Veverimer. The New Drug Application for the drug candidate was being reviewed under the Accelerated Approval Program. Tricida is looking to request a...
Read More 'CLDX' Stories Here
CLDX Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.7696 seconds.